Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem Settles Patent Suit With Luminex for $7.1M

NEW YORK (GenomeWeb) – Enzo Biochem today announced it has settled a patent infringement lawsuit the firm brought against Luminex.

Under the terms of the settlement, Luminex will pay Enzo $7.1 million to resolve a dispute over US patents 6,992,180; 7,064,197; and 8,097,405.

The abstract for the '180 patent states it is for phosphate-moiety labeled oligonucleotide reagents; the '197 patent is for non-porous solid supports for fixed or immobilized nucleic acids.

Luminex said in a Form 8-K filed today with the US Securities and Exchange Commission that it expects the settlement to decrease net earnings for the three months ended June 30, 2015 by approximately $5.2 million and diluted earnings per share by approximately $.12.

Enzo has sued Hologic, Affymetrix, Agilent, and Illumina over the '197 patent, and has sued Hologic, Abbott, Becton Dickinson, Life Technologies, and Roche over the '180 patent.               

In all, New York-based Enzo has brought 12 suits against various companies alleging patent infringement, the firm said in a statement, adding that the remaining 11 cases are still pending following the Luminex settlement. 

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.